Hypophosphatemic Rickets in Norway
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01057186|
Recruitment Status : Active, not recruiting
First Posted : January 27, 2010
Last Update Posted : August 31, 2016
|Condition or disease||Intervention/treatment|
|Hypophosphatemia, Familial Rickets Hyperphosphatemia||Dietary Supplement: Alfacalcidol; phosphate. Drug: Sevelamer|
|Study Type :||Observational|
|Estimated Enrollment :||80 participants|
|Official Title:||Hypophosphatemic Rickets in Norway|
|Study Start Date :||December 2009|
|Estimated Primary Completion Date :||December 2018|
Norwegian patients with hereditary hypophosphatemia.
Dietary Supplement: Alfacalcidol; phosphate.
Individual dosage form and dosage depending on phenotype and underlying cause.
Norwegian patients with hereditary hyperphosphatemia (hyperphosphatemic familial tumoral calcinosis and hyperphosphatemia hyperostosis syndrome).
Pills. Individual dosage depending on clinical symptoms/phenotype.
- Growth [ Time Frame: Up to 18 years ]Change i height z-score from time of diagnosis to last registered consultation.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01057186
|Haukeland University Hospital, Childrens departement|
|Bergen, Norway, 5021|
|Study Director:||Robert Bjerknes, Professor, MD, PhD||Haukeland University Hospital, Pediatric department|